Humer steps down as Roche CEO

Share this article:
Humer steps down
Humer steps down
Franz Humer stepped down as CEO of Roche on Tuesday passing over his duties to Severin Schwan, former head of the company's diagnostics unit.

Humer's resignation of duties was first announced in July 2007. He leaves behind a legacy of growth at Roche, helping the Swiss drugmaker become an industry leader in Europe.

Humer, a native of Austria, worked for Schering-Plough and GlaxoSmithKline before joining Roche in 1995. He became CEO three years later. 

Humer is credited with helping the company grow by establishing partnerships with biotech firms Genentech and Chugai and shepherding blockbusters MabThera, Avastin and Herceptin.

Humer will remain Roche's chairman and will also take the position of chairman at beverage company Diageo.

Incoming CEO Schwan said in his first speech as CEO that he plans to continue Roche's push into personalized medicine.

"Personalized medicine means that we can develop drugs which are more effective, safer and ultimately also more cost-effective," Schwan said during the company's annual meeting of shareholders.

Schwan also said that under his leadership, Roche will continue to be opposed to merging with another large pharma.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...